Hera is an associate of the capital markets department of Zhong Lun. She has been admitted to practice in Hong Kong and focuses on capital markets matters, including initial public offerings, public mergers and acquisitions, and regulatory compliance matters for listed companies.

Hera has represented both sponsors and issuers across diverse sectors, including technology, healthcare, consumer products, logistics and mobile gaming. She has worked on numerous securities offerings and corporate finance transactions, advising clients such as Sirnaomics* (stock code: 2257), Qingci Games Inc.* (stock code: 6633), LEPU ScienTech Medical Technology* (stock code: 2291), TechStar Acquisition Corporation* (stock code: 7855), Beijing Luzhu Biotechnology Co., Ltd.* (stock code: 2480), Edianyun Limited* (stock code: 2416), ZX Inc.* (stock code: 9890), and Xiamen Yan Palace Bioengineering Co., Ltd.* (stock code: 1497), among others. Additionally, she has provided legal services for leading enterprises in various industries, assisting in their compliance and transactional needs.

Prior to joining Zhong Lun, Hera acquired significant experience through internships at several reputable international firms and completed her training at a leading U.S. law firm.

• Advised the sole sponsor in relation to the IPO of Sirnaomics Ltd.*, an RNA therapeutics biopharmaceutical company with a strong presence in both China and the U.S., under Chapter 18A of the Listing Rules on the Main Board of the Hong Kong Stock Exchange
• Advised the joint sponsors in relation to the IPO of Qingci Games Inc.*, an established mobile game developer and publisher in China, on the Main Board of the Hong Kong Stock Exchange
• Advised LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*, an interventional medical device provider in China for congenital heart diseases, in relation to its IPO on the Main Board of the Hong Kong Stock Exchange
• Advised TechStar Acquisition Corporation*, a special purpose acquisition company, in relation to its IPO on the Main Board of the Hong Kong Stock Exchange, raising approximately HK$1.0 billion (US$128.5 million) from the offering
• Advised the sole sponsor in relation to the IPO of Beijing Luzhu Biotechnology Co., Ltd.*, a biotechnology company focusing on developing innovative vaccines and therapeutic biologics, under Chapter 18A of the Listing Rules on the Main Board of the Hong Kong Stock Exchange
• Advised the sole sponsor in relation to the IPO of Edianyun Limited*, a major office IT solution provider in China, on the Main Board of the Hong Kong Stock Exchange.
• Advised the joint sponsors in relation to the IPO of ZX Inc.*, a leading publisher of online games in China, on the Main Board of the Hong Kong Stock Exchange
• Advised Xiamen Yan Palace Bioengineering Co., Ltd.*, a leading consumer brand focusing on edible bird’s nest (EBN) products in China, in relation to its IPO on the Main Board of the Hong Kong Stock Exchange